Aspen Pharmacare shares up 11% on Covid-19 vaccine deal with Johnson & Johnson
JSE-listed Aspen Pharmacare has struck a deal with US multinational Johnson & Johnson to commercially manufacture its vaccine candidate.
Johnson & Johnson’s “Ad26.COV2-S” vaccine is undergoing clinical trials.
Aspen Pharmacare will make the vaccines at an existing factory in Port Elizabeth if trials are successful and manufacturing terms are finalised.
The facility is capable of making 300 million vaccine doses per year.
Aspen Pharmacare’s share price was up 11.45% on Monday.
The Money Show’s Bruce Whitfield interviewed Stephen Saad, CEO at Aspen Pharmacare.
Johnson & Johnson’s is a $400 billion company… We’re well-positioned… The tech transfer – we’ve started the process…Stephen Saad, CEO - Aspen Pharmacare
Johnson & Johnson… we like their candidate. You only need one shot… and a fridge… They’ve got 60 000 people in their Phase-3 trial…Stephen Saad, CEO - Aspen Pharmacare
Johnson & Johnson promised universal access…Stephen Saad, CEO - Aspen Pharmacare
We’ll be ready to put a vaccine into the world by March or April next year…Stephen Saad, CEO - Aspen Pharmacare
Listen to the interview in the audio below.
Pfizer is on the verge of cracking a Covid-19 vaccine, says Dr Glenda Gray, CEO at Medical Research Council.Read More
"The insured population is potentially emigrating," says Jessica Spira. But, the main concern is healthcare workers leaving.Read More
The lowest and highest-paid workers in SA haven’t yet recovered from the lockdown, according to FNB's Dr Christoph Nieuwoudt.Read More
The Money Show’s Bruce Whitfield interviews Famous Brands CEO Darren Hele.Read More
Futurist Graeme Codrington and economist Dick Forslund on how a 2nd hard lockdown and a 2nd Covid wave might affect our country.Read More
Social Development minister Lindiwe Zulu reflects on the concerning rise of the coronavirus infections.Read More
There were 15,028 new tests conducted and 22 new coronavirus-related deaths. New infections were 1.268.Read More
Your financial future – even if you have to start over – could be brighter than it would’ve been without the pandemic.Read More
The rand was just recently trading at a six-month high. Arabile Gumede interviews Bianca Botes (Peregrine Treasury Solutions).Read More
Bruce Whitfield interviews tourism consultant Gillian Saunders, a previous advisor to former Tourism Minister Derek Hanekom.Read More